Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Signed Informed Consent Form
Age ≥ 18 years
Documented ovarian, primary peritoneal, or fallopian tube carcinoma that has recurred
No prior chemotherapy in the recurrent setting
Measurable disease
Recovered from prior radiation therapy or surgery
You may not be if
Prior chemotherapy treatment for recurrent ovarian, primary peritoneal, or fallopian tube carcinoma
History of abdominal fistula, gastrointestinal perforation (GIP), or intra-abdominal abscess
Patients with clinical symptoms or signs of gastrointestinal (GI) obstruction or who require parenteral hydration, parenteral nutrition, or tube feeding
Patients with evidence of abdominal free air not explained by paracentesis or recent surgical procedure
Current, recent, or planned participation in an experimental drug study
History of systemic bevacizumab (Avastin) or other vascular endothelial growth factor (VEGF) or VEGF receptor-targeted agent use
Inadequately controlled hypertension
Prior history of hypertensive crisis or hypertensive encephalopathy
New York Heart Association Class II or greater congestive heart failure (CHF)
History of myocardial infarction or unstable angina
History of stroke or transient ischemic attack (TIA)
Known central nervous system (CNS) disease except for treated brain metastasis
Significant vascular disease or recent peripheral arterial thrombosis
History of hemoptysis
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
